Antibody-drug conjugates in breast cancer: current resistance mechanisms and future combination strategies

Abstract

Antibody-drug conjugates (ADCs), inspired by Paul Ehrlich’s “magic bullet” concept to target cancer cells with cytotoxic drugs while sparing healthy cells, represent a transformative approach in breast cancer therapy. From early agents (e.g., gemtuzumab ozogamicin) to second-generation trastuzumab emtansine (T-DM1) and third-generation trastuzumab deruxtecan (T-DXd)/disitamab vedotin (RC48), ADCs have demonstrated significant clinical benefits, including improved progression-free survival (PFS) and overall survival (OS) in breast cancer, with several approved for clinical use. Ongoing preclinical and clinical studies are rigorously exploring ADC combinations with molecular targeted agents, chemotherapy, and immunotherapy. However, de novo and acquired resistance remains a critical barrier to maximizing therapeutic efficacy. This review summarizes ADC mechanisms and clinical outcomes in breast cancer, explores resistance mechanisms, and dissects the biological rationale for combination strategies, aiming to identify novel payloads that enhance patient outcomes.

Keywords

Antibody-drug conjugates / breast cancer / treatment resistance / combination strategies

References

[1] Randall M,Rao R.A review of current and future antibody drug conjugates in breast cancer.Curr Treat Options Oncol2024;25:1506-16

[2] Verma S, Miles D, Gianni L, et al; EMILIA Study Group. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367:1783-91. PMCID:PMC5125250

[3] Hurvitz SA,Harbeck N.353 TiP HER2CLIMB-02: a randomized, double-blind, phase III study of tucatinib or placebo with T-DM1 for unresectable locally advanced or metastatic HER2+ breast cancer.Ann Oncol2020;31:S390

[4] Mamounas EP,Mano MS.Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE.Ann Oncol2021;32:1005-14

[5] Geyer CE Jr, Untch M, Huang CS, et al; KATHERINE Study Group. Survival with trastuzumab emtansine in residual HER2-positive breast cancer. N Engl J Med. 2025;392:249-57.

[6] Hurvitz SA,Chung WP.Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial.Lancet2023;401:105-17

[7] Cortés J,Im SA.Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial.Nat Med2024;30:2208-15 PMCID:PMC11333275

[8] Modi S, Jacot W, Yamashita T, et al; DESTINY-Breast04 Trial Investigators. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387:9-20. PMCID:PMC12065936

[9] Rugo HS,Tolaney SM.Health-related quality of life with sacituzumab govitecan in HR+/HER2- metastatic breast cancer in the phase III TROPiCS-02 trial.Oncologist2024;29:768-79 PMCID:PMC11379636

[10] Bardia A,Tolaney SM.Final results from the randomized phase III ASCENT clinical trial in metastatic triple-negative breast cancer and association of outcomes by human epidermal growth factor receptor 2 and trophoblast cell surface antigen 2 expression.J Clin Oncol2024;42:1738-44 PMCID:PMC11107894

[11] Bardia A, Jhaveri K, Im SA, et al; TROPION-Breast01 Investigators. Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer: primary results from TROPION-Breast01. J Clin Oncol. 2025;43:285-96. PMCID:PMC11771365

[12] Lu L,Chao Z,Chen K.Exploring the therapeutic potential of ADC combination for triple-negative breast cancer.Cell Mol Life Sci2023;80:350 PMCID:PMC11073441

[13] Housman G,Heerboth S.Drug resistance in cancer: an overview.Cancers2014;6:1769-92 PMCID:PMC4190567

[14] Dagogo-Jack I.Tumour heterogeneity and resistance to cancer therapies.Nat Rev Clin Oncol2018;15:81-94

[15] Gadaleta-Caldarola G,Santoro AN.Predictive factors of antibody-drug conjugate treatment in metastatic breast cancer: a narrative review.Cancers2024;16:4082 PMCID:PMC11640339

[16] Püsküllüoğlu M,Pacholczak-Madej R.Antibody-drug conjugates in HER-2 negative breast cancers with poor prognosis.Biochim Biophys Acta Rev Cancer2023;1878:188991

[17] Dumontet C,Senter PD,Beck A.Antibody-drug conjugates come of age in oncology.Nat Rev Drug Discov2023;22:641-61

[18] Hamilton GS.Antibody-drug conjugates for cancer therapy: the technological and regulatory challenges of developing drug-biologic hybrids.Biologicals2015;43:318-32

[19] Fu Z,Han S,Zhang Y.Antibody drug conjugate: the “biological missile” for targeted cancer therapy.Signal Transduct Target Ther2022;7:93 PMCID:PMC8941077

[20] Tsuchikama K.Antibody-drug conjugates: recent advances in conjugation and linker chemistries.Protein Cell2018;9:33-46 PMCID:PMC5777969

[21] Conilh L,Viricel W.Payload diversification: a key step in the development of antibody-drug conjugates.J Hematol Oncol2023;16:3 PMCID:PMC9847035

[22] Bhatti M,Milgrom LR,Chester KA.Targeted photodynamic therapy with multiply-loaded recombinant antibody fragments.Int J Cancer2008;122:1155-63

[23] Abelman RO,Spring LM,Bardia A.Mechanisms of resistance to antibody-drug conjugates.Cancers2023;15:1278 PMCID:PMC9954407

[24] Saleh K,Khalife N.Mechanisms of action and resistance to anti-HER2 antibody-drug conjugates in breast cancer.Cancer Drug Resist2024;7:22 PMCID:PMC11267152

[25] Loganzo F,Sung M.Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatments.Mol Cancer Ther2015;14:952-63

[26] Mosele F,Lusque A.Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial.Nat Med2023;29:2110-20 PMCID:PMC10427426

[27] Scaltriti M,Ocaña A.Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.J Natl Cancer Inst2007;99:628-38

[28] Phillips GDL,Li G.Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy.Clin Cancer Res2014;20:456-68

[29] Shvartsur A.Trop2 and its overexpression in cancers: regulation and clinical/therapeutic implications.Genes Cancer2015;6:84-105 PMCID:PMC4426947

[30] Coates JT,Leshchiner I.Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinical resistance to sacituzumab govitecan in triple-negative breast cancer.Cancer Discov2021;11:2436-45 PMCID:PMC8495771

[31] Sung M,Lu B.Caveolae-mediated endocytosis as a novel mechanism of resistance to trastuzumab emtansine (T-DM1).Mol Cancer Ther2018;17:243-53

[32] Baldassarre T,Craig AW.Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers.Breast Cancer Res2017;19:110 PMCID:PMC5627411

[33] Ríos-Luci C,Díaz-Rodríguez E.Resistance to the antibody-drug conjugate T-DM1 is based in a reduction in lysosomal proteolytic activity.Cancer Res2017;77:4639-51

[34] Tomabechi R,Sato T.SLC46A3 is a lysosomal proton-coupled steroid conjugate and bile acid transporter involved in transport of active catabolites of T-DM1.PNAS Nexus2022;1:pgac063 PMCID:PMC9896951

[35] Takegawa N,Yonesaka K.DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance.Int J Cancer2017;141:1682-9

[36] Sabbaghi M,Guardia C.Defective cyclin B1 induction in trastuzumab-emtansine (T-DM1) acquired resistance in HER2-positive breast cancer.Clin Cancer Res2017;23:7006-19

[37] Saatci Ö,Akbulut Ö.Targeting PLK1 overcomes T-DM1 resistance via CDK1-dependent phosphorylation and inactivation of Bcl-2/xL in HER2-positive breast cancer.Oncogene2018;37:2251-69

[38] Haag P,Lindberg ML,Lewensohn R.Deficient activation of Bak and Bax confers resistance to gemtuzumab ozogamicin-induced apoptotic cell death in AML.Exp Hematol2009;37:755-66

[39] Rosen DB,Cordeiro JA.AKT signaling as a novel factor associated with in vitro resistance of human AML to gemtuzumab ozogamicin.PLoS One2013;8:e53518 PMCID:PMC3539972

[40] Baselga J,Verma S.Relationship between tumor biomarkers and efficacy in EMILIA, a phase III study of trastuzumab emtansine in HER2-positive metastatic breast cancer.Clin Cancer Res2016;22:3755-63 PMCID:PMC5485412

[41] Zou Y,Chen B.crVDAC3 alleviates ferroptosis by impeding HSPB1 ubiquitination and confers trastuzumab deruxtecan resistance in HER2-low breast cancer.Drug Resist Updat2024;77:101126

[42] Jiang M,Xu B.Spotlight on ideal target antigens and resistance in antibody-drug conjugates: strategies for competitive advancement.Drug Resist Updat2024;75:101086

[43] Wei Q,Yang T.The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors.J Hematol Oncol2024;17:1 PMCID:PMC10768262

[44] Fuentes-Antrás J,Vijenthira A.Antibody-drug conjugates: in search of partners of choice.Trends Cancer2023;9:339-54

[45] Nicolò E,Ascione L.Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives.Cancer Treat Rev2022;106:102395

[46] Martin M,Dewar JA.Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study.Ann Oncol2016;27:1249-56

[47] Gelmon KA,Sablin M.Trastuzumab emtansine (T-DM1) plus capecitabine (X) in patients with HER2-positive MBC: MO28230 TRAX-HER2 phase 1 results.J Clin Oncol2014;32:606

[48] Patel TA,Rodriguez AA.Phase ib study of trastuzumab emtansine (TDM1) in combination with lapatinib and nab-paclitaxel in metastatic HER2-neu overexpressed breast cancer patients: stela results.J Clin Oncol2018;36:1035

[49] Patel TA,Creamer SL.A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study).Breast Cancer Res2019;21:100 PMCID:PMC6720931

[50] López-Miranda E,Di Cosimo S.Trastuzumab emtansine plus non-pegylated liposomal doxorubicin in HER2-positive metastatic breast cancer (Thelma): a single-arm, multicenter, phase Ib trial.Cancers2020;12:3509 PMCID:PMC7760511

[51] Perez EA,Eiermann W.Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2-positive advanced breast cancer: final results from MARIANNE.Cancer2019;125:3974-84

[52] Harbeck N,Barrios CH.Primary analysis of KAITLIN: a phase III study of trastuzumab emtansine (T-DM1) + pertuzumab versus trastuzumab + pertuzumab + taxane, after anthracyclines as adjuvant therapy for high-risk HER2-positive early breast cancer (EBC).J Clin Oncol2020;38:500

[53] Hurvitz SA,Jung KH.Neoadjuvant trastuzumab emtansine and pertuzumab in human epidermal growth factor receptor 2-positive breast cancer: three-year outcomes from the phase III KRISTINE study.J Clin Oncol2019;37:2206-16 PMCID:PMC6774816

[54] Andre F,Loi S.DESTINY-Breast07: dose-expansion interim analysis of T-DXd monotherapy and T-DXd + pertuzumab in patients with previously untreated HER2+ mBC.J Clin Oncol2024;42:1009

[55] Hurvitz SA,O’Shaughnessy J. HER2CLIMB-02: primary analysis of a randomized, double-blind phase 3 trial of tucatinib and trastuzumab emtansine for previously treated HER2-positive metastatic breast cancer. Available from: https://www.onclive.com/view/her2climb-02-primary-analysis-of-a-randomized-double-blind-phase-3-trial-of-tucatinib-and-trastuzumab-emtansine-for-previously-treated-her2-positive-metastatic-breast-cancer. [Last accessed on 9 Jun 2025]

[56] Freedman RA,Li T.Neratinib and ado-trastuzumab emtansine for pretreated and untreated human epidermal growth factor receptor 2 (HER2)-positive breast cancer brain metastases: Translational Breast Cancer Research Consortium trial 022.Ann Oncol2024;35:993-1002

[57] Hamilton E,Ochsenreither S.Trastuzumab deruxtecan with nivolumab in HER2-expressing metastatic breast or urothelial cancer: analysis of the phase Ib DS8201-A-U105 study.Clin Cancer Res2024;30:5548-58 PMCID:PMC11647201

[58] Fan Y,Li H.438 TiP Trastuzumab deruxtecan with pyrotinib in first-line HER2-positive unresectable or metastatic breast cancer: an exploratory, multi-center, single-arm, phase II study (TROPHY, trial in progress).Ann Oncol2024;35:S404-5

[59] Cardillo TM,Rossi DL,Mostafa AA.Synthetic lethality exploitation by an anti-trop-2-SN-38 antibody-drug conjugate, IMMU-132, plus PARP inhibitors in BRCA1/2-wild-type triple-negative breast cancer.Clin Cancer Res2017;23:3405-15

[60] Abelman RO,Niemierko A.Sequential combination of sacituzumab govitecan and talazoparib in metastatic triple negative breast cancer (mTNBC): results from a phase II study.J Clin Oncol2024;42:1102

[61] Haley B,Sahoo S.A phase I/Ib trial of PD 0332991 (palbociclib) and T-DM1 in HER2-positive advanced breast cancer after trastuzumab and taxane therapy.Clin Breast Cancer2021;21:417-24

[62] Spring LM,Li T.Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer.NPJ Breast Cancer2021;7:103 PMCID:PMC8339067

[63] Torres ETR.Emerging combination immunotherapy strategies for breast cancer: dual immune checkpoint modulation, antibody-drug conjugates and bispecific antibodies.Breast Cancer Res Treat2022;191:291-302

[64] Emens LA,Beresford M.Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial.Lancet Oncol2020;21:1283-95

[65] Hamilton EP,Falkson C.Impact of anti-HER2 treatments combined with atezolizumab on the tumor immune microenvironment in early or metastatic breast cancer: results from a phase Ib study.Clin Breast Cancer2021;21:539-51

[66] Hamilton EP,Boni V.162O Primary analysis from DS8201-A-U105: a 2-part, open label, phase Ib trial assessing trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing advanced breast cancer.Ann Oncol2022;33:S196

[67] Schmid P,Armstrong A.BEGONIA: phase 1b/2 study of durvalumab (D) combinations in locally advanced/metastatic triple-negative breast cancer (TNBC) - initial results from arm 1, d+paclitaxel (P), and arm 6, d+trastuzumab deruxtecan (T-DXd).J Clin Oncol2021;39:1023

[68] Harbeck N, Nitz UA, Christgen M, et al; WSG-ADAPT investigators. De-escalated neoadjuvant trastuzumab-emtansine with or without endocrine therapy versus trastuzumab with endocrine therapy in HR+/HER2+ early breast cancer: 5-year survival in the WSG-ADAPT-TP trial. J Clin Oncol. 2023;41:3796-804.

[69] Jhaveri K,Hamilton E.Abstract RF02-03: trastuzumab deruxtecan (T-DXd) in combination with anastrozole or fulvestrant in patients with HER2-low HR+ advanced/metastatic breast cancer: a Phase 1b, open-label, multicenter, dose-expansion study (DESTINY-Breast08).Cancer Res2024;84:RF02-03

[70] Debbi K,Medioni J.Safety and efficacy of combined trastuzumab-deruxtecan and concurrent radiation therapy in breast cancer. The TENDANCE multicentric French study.Breast2025;80:104421 PMCID:PMC11893322

[71] Stumpf PK,Robin TP.Combination of trastuzumab emtansine and stereotactic radiosurgery results in high rates of clinically significant radionecrosis and dysregulation of aquaporin-4.Clin Cancer Res2019;25:3946-53 PMCID:PMC6751332

[72] Hurvitz S,O’haughnessy J.Abstract GS01-10: HER2CLIMB-02: randomized, double-blind phase 3 trial of tucatinib and trastuzumab emtansine for previously treated HER2-positive metastatic breast cancer.Cancer Res2024;84:GS01-10